Skip to main content

Table 3 Risk for significant second primary cancers by age at diagnosis of uterine cancer (left half) and follow-up interval (right half), respectively

From: Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period

SPM site (ICD-9 code) Agea (years) O E SIR (O/E) 95 % CI Intervalb (years) O E SIR (O/E) 95 % CI
Small intestine (152) <50 7 0.27 26.06 (10.44, 53.71) ≤5 6 0.23 25.95 (9.48-56.49)
≥50 5 1.15 4.34 (1.40, 10.14) ≤1 0 0.03 0 NA
      1-5 6 0.20 29.47 (10.76-64.15)
      5-10 3 0.38 7.97 (1.60-23.30)
      ≥10 3 0.81 3.69 (0.74-10.79)
Colorectum (153,154) <50 36 9.68 3.72 (2.60, 5.15) ≤5 58 9.00 6.45 (4.89-8.33)
≥50 83 43.36 1.91 (1.52, 2.37) ≤1 12 1.07 11.25 (5.81-19.66)
      1-5 46 7.93 5.8 (4.25-7.74)
      5-10 29 14.05 2.06 (1.38-2.96)
      ≥10 32 30.00 1.07 (0.73-1.51)
Lung (162) <50 13 6.24 2.08 (1.11, 3.56) ≤5 36 6.22 5.78 (4.05-8.00)
≥50 59 30.57 1.93 (1.47, 2.49) ≤1 7 0.74 9.42 (3.77-19.40)
      1-5 29 5.48 5.29 (3.54-7.59)
      5-10 24 9.73 2.47 (1.58-3.67)
      ≥10 12 20.85 0.58 (0.30-1.01)
Breast (174) <50 34 29.38 1.16 (0.80, 1.62) ≤5 52 13.71 3.79 (2.83-4.97)
≥50 61 37.13 1.64 (1.26, 2.11) ≤1 12 1.40 8.56 (4.42-14.96)
      1-5 42 12.31 3.25 (2.32-4.43)
      5-10 21 20.05 1.05 (0.65-1.60)
      ≥10 22 32.75 0.67 (0.42-1.02)
Ovary (183) <50 23 3.68 6.25 (3.96, 9.38) ≤5 37 1.84 20.12 (14.16-27.73)
≥50 17 5.97 2.85 (1.66, 4.56) ≤1 30 0.20 152.87 (103.12-218.25)
      1-5 7 1.64 4.26 (1.71-8.78)
      5-10 1 2.78 0.36 (0.00-2.00)
      ≥10 2 5.03 0.40 (0.04-1.44)
Vagina (184) <50 6 0.38 15.68 (5.73, 34.14) ≤5 7 0.29 24.43 (9.79-50.34)
≥50 10 1.38 7.22 (3.46, 13.29) ≤1 6 0.04 172.12 (62.85-374.65)
      1-5 1 0.25 3.97 (0.05-22.11)
      5-10 3 0.46 6.58 (1.32-19.23)
      ≥10 6 1.02 5.86 (2.14-12.75)
Bladder (188) <50 5 1.07 4.69 (1.51, 10.95) ≤5 7 1.22 5.74 (2.30-11.82)
≥50 13 6.72 1.93 (1.03, 3.31) ≤1 3 0.15 19.69 (3.96-57.52)
      1-5 4 1.07 3.75 (1.01-9.59)
      5-10 4 1.99 2.01 (0.54-5.14)
      ≥10 7 4.58 1.53 (0.61-3.15)
Kidney (189) <50 4 1.68 2.38 (0.64, 6.10) ≤5 7 1.82 3.86 (1.54-7.95)
≥50 21 9.47 2.22 (1.37, 3.39) ≤1 6 0.22 27.70 (10.12-60.30)
      1-5 1 1.60 330.63 (0.01-3.48)
      5-10 9 2.93 3.07 (1.40-5.82)
      ≥10 9 6.40 1.41 (0.64-2.67)
Total <50 128 52.37 2.44 (2.04, 2.91) ≤5 210 34.33 6.12 (5.32,7.00)
≥50 269 135.77 1.98 (1.75, 2.23) ≤1 76 3.84 19.80 (15.60-24.75)
       1-5 134 30.50 4.39 (3.68-5.21)
       5-10 94 52.37 1.79 (1.45, 2.20)
       ≥10 93 101.45 0.92 (0.74, 1.12
  1. Bold indicates statistical significance
  2. SIR standardized incidence ratio, SPM second primary malignancy, O observed numbers of SPMs, E expected numbers of SPMs, CI confidence interval
  3. aAge at diagnosis of uterine cancer
  4. bFollow-up interval after the diagnosis of uterine cancer